Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

TiNT : A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

0-25Age 0-25

Brain and Spinal<br/>CancersCancer LocationBrain and Spinal
Cancers

Systemic therapy | Brain and spinal cordGlioma

Trial Overview Read MoreRead more

This phase II trial is evaluating the effectiveness of a targeted therapy (trametinib) in children, teenagers and young adults with neurofibromatosis type 1 (NF1) associated Plexiform Neurofibromas and Optic Pathway Gliomas.
 

This trial is treating patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas

Cooperative Group

Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG)

Summary

This trial has two cohorts. Cohort 1 will consist of people with Neurofibromatosis Type 1 associated Plexiform Neurofibroma (NF1-PN). Cohort 2 will consist of people with Neurofibromatosis Type 1 associated Optic Pathway Glioma (NF1-OPG). To be eligible, participants must be aged between 3 months and 25 years. All participants will receive trametinib either as an oral tablet or an oral solution. Trametinib will be administered at a dose of 0.025mg/kg once daily for children 6 years and over, and at a dose of 0.032mg/kg once daily for children under 6 years.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next